Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Ashish Manne

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2356-5162; OpenAlex author ID A5049484010, A5096950690. Sources: ClinicalTrials.gov.

Their work

Papers
19 (first author 2, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers, 1 trial · 2025: 5 papers · 2026: 8 papers

Papers 19

  1. Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Databas… Co-author DOI 10.14701/ahbps.25-209↗
  2. Polygenic Risk Scores for Pancreatic Cancer Risk Prediction and Early Detection: A Systematic Evidence Review of Clinical Utility Co-author DOI 10.20944/preprints202610.1580.v1↗
  3. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.21203/rs.3.rs-8545050/v1↗
  4. Metastatic Pancreatic Adenocarcinoma with Germline BLM and Somatic ATM Mutations: A Case Report and Review of DNA Damage Response. Co-author DOI 10.29011/2574-7754.102521↗
  5. Genomic Biomarkers for First-Line Treatment Selection in Metastatic Pancreatic Ductal Adenocarcinoma: A Narrative Review. Last author DOI 10.3390/cancers18101664↗
  6. Molecular Characterization of Small Extracellular Vesicles in Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Stereotactic Body Ra… Co-author DOI 10.3390/cancers18111704↗
  7. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.64898/2026.01.06.26343539↗
  8. Transcriptomic Profiling and Demographic Analysis of Appalachian Patients with Pancreatic Ductal Adenocarcinoma using the Purity Independent Subtyping of Tumor… Co-author DOI 10.64898/2026.09.22.26363302↗
  9. Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Co-author DOI 10.1016/j.hpb.2025.08.015↗
  10. Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.1097/xcs.0000000000001277↗
  11. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Co-author DOI 10.3389/fonc.2025.1544928↗
  12. Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review. First author DOI 10.3389/fonc.2025.1555963↗
  13. Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies. First author DOI 10.3390/cancers17040589↗
  14. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  15. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  16. Differential Expression and Diagnostic Value of MUC5AC Glycoforms in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15194832↗
  17. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence. Co-author DOI 10.3390/ijms24098087↗
  18. Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time? Last author DOI 10.3390/cancers14143453↗
  19. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13123059↗

Trials 1

  1. A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma Principal investigator NCT05624918↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ashwini Kumar Esnakula · 8 shared papers, 2021–2026 · strength 1.73
  2. Ravi Kumar Paluri · 6 shared papers, 2023–2026 · strength 1.41
  3. Upender Manne · 6 shared papers, 2024–2026 · strength 1.35
  4. Anne M. Noonan · 6 shared papers, 2024–2026 · strength 1.31
  5. Jordan M. Cloyd · 6 shared papers, 2024–2026 · strength 1.23
  6. Anup Kasi · 5 shared papers, 2023–2026 · strength 1.09
  7. Mary E. Dillhoff · 5 shared papers, 2024–2026 · strength 1.02
  8. Timothy Michael Pawlik · 4 shared papers, 2025–2026 · strength 0.93
  9. Deepak Sherpally · 3 shared papers, 2024–2025 · strength 0.90
  10. Aslam M. Ejaz · 4 shared papers, 2024–2026 · strength 0.81
  11. Shafia Rahman · 4 shared papers, 2024–2026 · strength 0.79
  12. Lianbo Yu · 4 shared papers, 2023–2025 · strength 0.75
  13. Ankur Sheel · 4 shared papers, 2022–2025 · strength 0.74
  14. Eric David Miller · 3 shared papers, 2024–2025 · strength 0.61
  15. Ronit Juthani · 1 shared paper, 2025 · strength 0.54
  16. Muhammad Khalid Khan Niazi · 2 shared papers, 2026 · strength 0.53
  17. Abdul Akbar · 2 shared papers, 2026 · strength 0.53
  18. Susan Tsai · 2 shared papers, 2026 · strength 0.53
  19. Vaibhav Sahai · 2 shared papers, 2026 · strength 0.53
  20. Kannan Thanikachalam · 3 shared papers, 2024–2025 · strength 0.51
  21. Wancai Yang · 3 shared papers, 2024–2025 · strength 0.51
  22. Anushareddy Muddasani · 1 shared paper, 2026 · strength 0.50
  23. Patrick W. Underwood · 2 shared papers, 2025 · strength 0.45
  24. Laith I. Abushahin · 2 shared papers, 2021–2026 · strength 0.45
  25. Allan Tsung · 2 shared papers, 2021–2023 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.